About

Lanny L. Johnson, M.D. discovered the potential of A-Costmetic’s benefit to skin health.

Dr. Johnson is an internationally recognized orthopedic surgeon. As such he is an inventor and holder of more than 75 US patents in medicine and surgery. He was one of the pioneers in arthroscopic surgery and the inventor of the motorized instrumentation still used world-wide today in all such surgical procedures. He invented the first non-reactive bioabsorbable implants for orthopedic surgery. He founded a surgical specialty company, Instrument Makar, Inc. This was sold to Smith+Nephew in 2002. He is the founder of the parent company of A-Cosmetic; Anti-Oxidant USA Research and Development. We at AntiOxidant USA Research and Development (AOUSA R&D) are committed to well being.  Our founder Dr. Johnson continues to make a difference in health care.  In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.

In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.

Johnson LL. What’s Important: Making a Difference May Include Being Different. J Bone Joint Surg. 2018 Mar 7; 100 (5): 443. DOI 10.2106/JBJS.18.00011.

https://www.jbjs.org/reader.php?source=The_Journal_of_Bone_and_Joint_Surgery/100/5/443/fulltext&id=31139&rsuite_id=1597649#info
or  http://drlanny.com/physiciansurgeon/making-a-difference-may-include-being-different/

After concluding his clinical practice, he has continued his interest in medical research and development. In 2005, upon learning that the dyes found in cherries would stimulate rodent pancreatic cells to produce insulin, he reasoned there may be other applications. Independent studies at Scripps Institute in La Jolla, California confirmed his hypothesis that these dyes would cause the human joint lining to turn on the growth hormone gene for Insulin Like Growth Factor-1. IGF-1 has long been known to heal articular cartilage. This resulted in US patents for intra articular injection treatment of degenerative arthritis; i.e. knee, hip, shoulder, etc. The patents were a follows:

8, 263,069 Compositions including anthocyanin or anthocyanidins for the prevention or treatment of articular cartilage-associated conditions. September 11, 2012.

9,486,468: Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions. November 8, 2016

While waiting for these patents to be issued, he learned from the medical literature that various plant extracts having these dyes, anthocyanins and anthocyanidins had antibacterial properties. He commissioned independent in vitro laboratory studies that showed the parent dyes were weak antibiotics. However, the primary metabolites; protocatechuic acid (PCA) and 2,4,6 tri-hydroxybenzaldehyde (246THBA) were very powerful broad-spectrum antibiotics. The subsequent metabolites, vanillic and hippuric acid had few antibiotic properties.

As a result of these studies he was granted a US patent on these primary metabolites for their antibiotic and wound healing properties.

9,498,413: B2 Antimicrobials and methods of use thereof for wound healing. November 22, 2016.

Collagen production and scar reduction: These studies on wound healing also demonstrated that PCA would produce more collagen in the skin following tape stripping of the rodent skin. This study method replicated the clinical procedures of exfoliation or dermabrasion. US patent claims have been granted for this application as USA patent No. 9,925,152 that was issued on March 27, 2018.

Control Human Skin Acne: Subsequently, he funded a two-year, four phase human proof of principle study in attempt to sanitize the skin in human volunteers at Loma Linda Medical School. This was performed on medical student volunteers. He was seeking a means of disinfecting the human skin prior to surgery since the bacteria of the skin are one source of surgical infections. Attention was given especially to Propionibacterium acnes which in recent years as emerged as the bacteria uniquely causing shoulder and spine surgery infections. One result from these studies was the discovery of an antioxidant formulation that would control the various potential pathogens on normal skin while preserving the commensal normal bacteria.

He also commissioned studies at WuXiapptec of Marietta GA from which he learned that PCA in certain concentrations would destroy the biofilm covered colonies of serious pathogens; Methicillin Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. This led to US patents granted concerning the coating of medical and surgical implants to prevent wound infections following total knee and total hip surgery.

He has an application underway with the Environmental Protection Agency concerning a spray for hard surfaces that will be helpful in hospitals and clinics to sanitize these environments of pathological microbes.

He envisions PCA as being the basis for a new industry, addressing multiple health, humanitarian and societal problems.

He launched OAUSA R&D in 2018 to meet those needs.

Patents

The following patents are in this portfolio as of August 31, 2021.  The specific claims of each may be view under the patent number at https://patft.uspto.gov/netahtml/PTO/srchnum.htm

September 11, 2012.  This patent showed that the dyes of plants (anthocyanins and anthocyanins) the precursor of the metabolite protocatechuic acid turned on the gene for growth hormone IGF-1 in human synovium.

November 8, 2016.  This patent secured the intra articular injection route not previously included in the granted patent claims for cyanidin-3-glucoside.

November 22, 2016.  This was the parent patent showing broad spectrum antibiotic properties and wound healing acceleration.  See the illustrations above.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

May 15, 2018.  This patent secures that protocatechuic acid can only be manufactured and delivered to an end user by the owner of this patent.

 

June 5, 2018.  This patent was a continuation of 9,925,152 that now allowed for intra-articular injection.

July 26, 2018.  This patent included the metabolites of protocatechuic acid and 2,4,6 trihydroxybenzaldehyde for the destruction of biofilms of MRSA and Pseudomonas on metal, cloth and ceramic.

July 26, 2018.  This was an expansion of 10,004,705 applications.

July 10, 2018. This patent expanded the formulation for treatment of implants to include protocatechuic acid, 70% isopropyl alcohol, propylene glycol, and an essential oil.

July 31, 2018. This patent includes the chemical formulation of 10,016,380 for medical and surgical implants, dental implants and instrumentation.  The later for spaying or soaking in solution.

December 4, 2018. This patent secures the use of PCA to  coat a bandage or dressing at time or treatment and or a commercial preparation for as stated in claim #22 if a wound is a burn, skin break, bone break, muscle tear, puncture, surgical incision site, microdermabrasion site, skin graft site, a wound associated with diabetes, a bed sore, a pressure sore, skin defoliation, or a laceration, and wherein the protocatechuic acid becomes activated by contact with moisture from the wound.

April 23, 2019. An extension of prior claims that specifically cite PCA as an antibacterial for Propionibacterium acnes.  This for the treatment of skin acne.

May 21, 2019.   This patent extends the use of PCA to the food industry.

September 3, 2019. This is a non-surgical method of loosening biofilms from an implant via ultrasound and then treating without surgery.  The treatment would be repeated needle aspirations for infection status and then injection of protocatechuic acid crystals to destroy the biofilms attached to the implant.

October 1, 2019. This is an extension and further specification of the skin penetration formulation claims for pre-operative skin disinfection and facial acne with concentration above 10%.

September 5, 2020.  This is an extension that includes the disinfectant and sanitizer use emphasizing the residual anti-microbial protocatechuic acid coating the remains on the article and or person after the evaporation of the liquid vehicle.

 

March 30, 2021.  The treatment of COVID19 virus with protocatechuic acid.  This patent is for treating the patient; oral, intravenous, injection, etc.  Working toward regulations approvals.

August 31, 2021.  Anti-microbials and the Methods and Use thereof. This patent is for mitigation of bacteria and virus (COVID 19) by coating of personal protective equipment; masks, gowns, hats, shoes, etc.